Skip to main content
Clinical Trials/NCT00893659
NCT00893659CompletedNot Applicable

The Effect of Beta-glucan on Faecal Microflora in Polypectomized Patients

Harokopio University1 site in 1 country69 target enrollmentStarted: January 1, 2009Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
69
Locations
1
Primary Endpoint
To measure the effect of beta-glucan on fecal microflora (number of bacteria, bacterial enzyme activity, SCFA, pH).

Study Overview

Brief Summary

The aim of this study is to determine the effect of the potential prebiotic beta-glucan on the intestinal microflora, the bacterial enzyme activity (beta-glucuronidase and beta-glucosidase) in the feces, the fecal pH and the concentration of fecal short-chain fatty acid in polypectomized patients. Also the in vitro anti-cyto- and anti-genotoxicity of fecal water will be examined on human cell culture (HT29). During the trial, patient's clinical symptoms (intestinal habits), physical activity, well-being and food intake will be recorded.

Detailed Description

Prebiotics, such as short- and long-chain fructo-oligosaccharides are fermented by the microflora colonizing the gastrointestinal tract, and they selectively stimulate the growth or the activity of one or limited number of bacteria within the intestine. Beta-glucans are polysaccharides occurring in the bran of cereal grains, the cell wall of Saccharomyces cerevisiae and bacteria, certain types of fungi, seaweed and many kinds of mushrooms. The aim of this study is to determine the effect of the potential prebiotic beta-glucan on the intestinal microflora, the bacterial enzyme activity (beta-glucuronidase and beta-glucosidase) in the faeces, the faecal pH, and the concentration of faecal short-chain fatty acid in polypectomized patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
20 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •The subjects must have biopsy and histologically confirmed adenomatous polyps ≥ 1cm in size or ≥ 3 in number with moderate or severe dysplasia

Exclusion Criteria

  • •Subjects ≥ 75 years of age
  • •Subjects who are pregnant or desire to become pregnant during the study period
  • •Subjects who are considered to be poor clinic attendees
  • •Subjects who have been on antibiotics within the previous month or are likely to require antibiotics during the trial
  • •Subjects who consume prebiotics or probiotics within the previous month or are likely to require antibiotics during the trial
  • •Subjects with colon cancer
  • •Subjects with additional gastrointestinal disorders (e.g., Crohn's disease or ulcerative colitis)
  • •Subjects with malignancy or any end-stage organ disease

Arms & Interventions

wheat bread without beta-glucan

Placebo Comparator

Intervention: wheat bread without beta-glucan (Dietary Supplement)

wheat bread with beta-glucan supplementation

Experimental

Intervention: wheat bread with beta-glucan (Dietary Supplement)

Outcomes

Primary Outcomes

To measure the effect of beta-glucan on fecal microflora (number of bacteria, bacterial enzyme activity, SCFA, pH).

Time Frame: four months

To observe the effect of beta-glucan on intestinal symptoms and well-being.

Time Frame: four months

Secondary Outcomes

  • To study the fecal water cyto- and/or genotoxicity on HT-29 cell line.(one year)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Kyriacou Adamantini

Assistant Professor

Harokopio University

Study Sites (1)

Loading locations...

Similar Trials